| 07 Jun 2023 |
PR Newswire |
 Actinogen to present progress on Cognitive Impairment in Depression and Alzheimer’s Disease Phase 2 trials at the BIO International Convention |
| 31 May 2023 |
PR Newswire |
Actinogen to present progress on Cognitive Impairment in Depression and Alzheimer’s Disease Phase 2 trials at the BIO International Convention |
| 31 May 2023 |
Yahoo Finance |
Actinogen to present progress on Cognitive Impairment in Depression and Alzheimer’s Disease Phase 2 trials at the BIO International Convention |
| 30 Mar 2023 |
PR Newswire |
Actinogen presents positive Phase 2a Xanamem data at AD/PD™ Alzheimer’s and Parkinson’s diseases conference |
| 01 Mar 2023 |
Biotech Daily |
Actinogen Appoints Nicki Vasquez Non-Executive Director |
| 01 Feb 2023 |
Biotech Daily |
Actinogen Appoints Dr Dana Hilt CMO |
| 22 Dec 2022 |
Biotech Daily |
FDA Okays Actinogen 6-Months Xanamem Phase IIb Alzheimer’s Trial |
| 22 Dec 2022 |
Seeking Alpha |
FDA agrees to Actinogen six-month Phase 2b Alzheimer’s Disease trial |
| 22 Dec 2022 |
PR Newswire |
FDA agrees to Actinogen six-month Phase 2b Alzheimer’s Disease trial |
| 22 Dec 2022 |
MarketWatch |
FDA agrees to Actinogen six-month Phase 2b Alzheimer’s Disease trial |
| 22 Dec 2022 |
Yahoo |
FDA agrees to Actinogen six-month Phase 2b Alzheimer’s Disease trial |
| 22 Dec 2022 |
The Market Herald |
Actinogen Medical (ASX:ACW) receives FDA approval for six-month phase 2b Alzheimer trial |
| 22 Dec 2022 |
BioSpace |
FDA agrees to Actinogen six-month Phase 2b Alzheimer’s Disease trial |
| 15 Dec 2022 |
Yahoo Finance |
Actinogen announces first patient treated in depression and cognitive impairment Phase 2 clinical trial |
| 15 Dec 2022 |
Daily Bulletin |
Actinogen announces first patient treated in depression and cognitive impairment Phase 2 clinical trial |
| 15 Dec 2022 |
BioPharma APAC |
Actinogen announces first patient treated in depression and cognitive impairment Phase 2 clinical trial |
| 14 Dec 2022 |
PR Newswire |
Actinogen announces first patient treated in depression and cognitive impairment Phase 2 clinical trial |
| 14 Dec 2022 |
BioSpace |
Actinogen announces first patient treated in depression and cognitive impairment Phase 2 clinical trial |
| 08 Dec 2022 |
Biotech Daily |
Actinogen Treats First Xanamem Depression Patient |
| 25 Nov 2022 |
Biotech Daily |
Dr Boreham’s Crucible: Actinogen Medical |
| 21 Oct 2022 |
Yahoo Finance |
Actinogen Medical: re-initiation — Cognitive enhancer targeting key diseases |
| 19 Oct 2022 |
Stockhead |
Alzheimer’s drug no longer a moonshot as race heats up, ASX-listed Actinogen in the running |
| 19 Oct 2022 |
FN Arena |
Australian Broker Call *Extra* Edition – Oct 19, 2022 |
| 12 Oct 2022 |
Outsourcing-Pharma.com |
“Significant Step Forward” for Actinogen’s Alzheimer’s treatment |
| 11 Oct 2022 |
EIN Presswire |
Actinogen Medical (ACW) announces large Xanamem® therapeutic effect in early-stage Alzheimer’s Disease (AD) patients |
| 11 Oct 2022 |
BioWorld |
Biomarker analysis yields clinical benefit for Actinogen’s Xanamem in Alzheimer’s disease |
| 10 Oct 2022 |
The Market Herald |
Actinogen Medical (ASX:ACW) finds positive results in phase 2A trial of Xanamem on Alzheimers |
| 10 Oct 2022 |
BioSpace |
Clinical Catch-Up: Actinogen, Applied Therapeutics, BrainStorm, Immatics, and More |
| 10 Oct 2022 |
Labiotech.eu |
Positive data indicates likely therapeutic effect of Alzheimer’s drug |
| 10 Oct 2022 |
Biotech Daily |
Actinogen Xanamem Alzheimer’s Biomarker Effect |
| 10 Oct 2022 |
The Motley Fool |
Why Actinogen, Core Lithium, Fortescue, and Galileo Mining shares are pushing higher |
| 10 Oct 2022 |
The Motley Fool |
Guess which ASX biotech share just rocketed 56% on new Alzheimer’s drug trial results |
| 10 Oct 2022 |
Market Screener |
Actinogen Medical Validates Efficacy of Alzheimer’s Disease Therapy; Shares Surge 30% |
| 10 Oct 2022 |
ShareCafe |
Stocks of the Hour: HLX, ACW, GAL |
| 10 Oct 2022 |
Market Index |
Actinogen up 30% on strong Alzheimer’s trial results, says Xanamem product can slow progression |
| 10 Oct 2022 |
PR Newswire |
Actinogen Medical Limited (ACW) announces large Xanamem therapeutic effect in early-stage Alzheimer’s Disease (AD) patients |
| 29 Sep 2022 |
Stocks Down Under |
Actinogen Medical (ASX: ACW): Good news on phase 2 trials can catapult this stock |
| 14 Jul 2022 |
Mirage News |
Actinogen confirms Alzheimer’s disease biomarker study timing and design |
| 27 Jun 2022 |
FN Arena |
Australian Broker Call *Extra* Edition – Jun 27, 2022 | Bell Potter initiates coverage on Australian drug developer Actinogen Medical |
| 14 Jun 2022 |
The Market Herald |
Actinogen Medical (ASX:ACW) announces phase two trial designs for AD & MDD |
| 14 Jun 2022 |
Biotech Daily |
Actinogen Medical Plans Xanamem For Alzheimer’s, Depression Phase II Trials |
| 14 Jun 2022 |
The Sentiment |
Why one contentious FDA drug approval is good news for Actinogen Medical |
| 14 Jun 2022 |
IQ Stock |
Actinogen Announces Phase 2 Trials in Alzheimer’s Disease and Depression |
| 14 Jun 2022 |
Global Newswire |
Actinogen Announces Phase 2 Trials in Alzheimer’s Disease and Depression |
| 14 Jun 2022 |
Yahoo Finance |
Actinogen Announces Phase 2 Trials in Alzheimer’s Disease and Depression |
| 14 Jun 2022 |
Biospace |
Actinogen Announces Phase 2 Trials in Alzheimer’s Disease and Depression |
| 04 May 2022 |
The Market Herald |
Actinogen (ASX:ACW) prioritises Alzheimers disease and depression trials |
| 04 May 2022 |
Market Index |
Actinogen reassesses its priorities: Clinical programs refocus on cognition |
| 02 May 2022 |
Aged Care Insite |
Is Xanamem the Alzheimer’s breakthrough we’ve all been waiting for? |
| 28 Apr 2022 |
Eminetra Australia |
Positive test results for Alzheimer’s drug Xanamem |
| 28 Apr 2022 |
TechInvest |
Actinogen announces positive XanaMIA Part A trial |
| 28 Apr 2022 |
Aged Care News |
Millions could benefit after breakthrough Alzheimer’s treatment trial by Aussie biotech |
| 28 Apr 2022 |
Hospital and Healthcare |
Positive trial results for Alzheimer’s drug Xanamem |
| 27 Apr 2022 |
Biotech Daily |
Actinogen XanaMIA Phase 1B Part A Trial Meets Endpoints |
| 27 Apr 2022 |
The Sentiment |
New trial results from Actinogen hold promise for Alzheimer’s treatment |
| 27 Apr 2022 |
The Market Herald |
Actinogen Medical (ASX:ACW) reports positive XanaMIA Part A trial topline results |
| 27 Apr 2022 |
Kalkine Media |
Actinogen gets upbeat results from Xanamem trial for Alzheimer’s treatment |
| 27 Apr 2022 |
Mirage News |
Millions worldwide could benefit after breakthrough trial in treatment for Alzheimer’s |
| 27 Apr 2022 |
Australian Associated Press |
Millions worldwide could benefit after a breakthrough trial in the treatment for Alzheimer’s |
| 27 Apr 2022 |
news.com.au |
Millions worldwide could benefit after a breakthrough trial in the treatment for Alzheimer’s |
| 27 Apr 2022 |
The Australian |
Millions worldwide could benefit after a breakthrough trial in the treatment for Alzheimer’s |
| 27 Apr 2022 |
The National Tribune |
Millions worldwide could benefit after breakthrough trial in treatment for Alzheimer’s |
| 27 Apr 2022 |
Actinogen |
Media Release: Millions worldwide could benefit after a breakthrough trial in the treatment for Alzheimer’s by Aussie biotech Actinogen |
| 26 Apr 2022 |
Clinical Trials Arena |
Pipeline Moves: Actinogen makes strides in mild cognitive impairment |
| 11 Feb 2022 |
The Market Herald |
Actinogen Medical (ASX:ACW) advances Alzheimer’s treatment |
| 09 Feb 2022 |
The Sentiment |
Actinogen appoints leading researchers to conduct Phase 2 trials for treatment of Fragile X Syndrome |
| 09 Feb 2022 |
The Market Herald |
Actinogen Medical (ASX:ACW) locks in trial manager for FXS phase-two study |
| 09 Feb 2022 |
Biotech Daily |
Worldwide To Manage Xanamem Fragile X Trial |
| 22 Dec 2021 |
Stockhead |
Healthcare has been a hot sector. Here are the top ASX biotech stocks in 2021. Best performing ASX biotechs in 2021. |
| 07 Dec 2021 |
The Market Herald |
Actinogen Medical (ASX:ACW) partners with Oxford University |
| 07 Dec 2021 |
Stockhead |
ASX Health Stocks: Neuren stock price up 100pc on positive Phase 3 results In other ASX health news this morning: Actinogen Medical (ASX:ACW) has announced strategic collaboration with Oxford University researchers A |
| 29 Nov 2021 |
The Sentiment |
Better than a sudoku: could this drug be the key to preventing Alzheimer’s? |
| 15 Jul 2021 |
Stockhead |
These two ASX brain health stocks, boosted by FDA’s approval of Adulhelm, are kicking off clinical trials |
| 15 Jul 2021 |
Biotech Daily |
Actinogen Enrols 1st XanaMIA Trial Patient |
| 15 Jul 2021 |
The Market Herald |
Actinogen Medical (ASX:ACW) enrols first patient in Alzheimer’s Disease trial |
| 15 Jul 2021 |
Monex Trading the World |
Here’s why the Actinogen (ASX:ACW) share price is rocketing 13% today |
| 09 Jul 2021 |
Fragile X News Today |
FDA OKs Phase 2 Trial Design for Xanamem |
| 23 Jun 2021 |
Stockhead |
Actinogen Medical gets a further boost from supportive FDA advice, shares up 7-fold in 2021 |
| 22 Jun 2021 |
The Motley Fool |
Here’s why the Actinogen Medical (ASX:ACW) share price is up 20% |
| 21 Jun 2021 |
Biotech Daily |
Actinogen Appoints 2 CROs, Cogstate For XanaMIA |
| 21 Jun 2021 |
The Market Herald |
Actinogen Medical (ASX:ACW) takes next step towards cortisol study |
| 21 Jun 2021 |
Stockhead |
Dr Boreham’s Crucible: Time to make a song and dance about Actinogen (ASX:ACW)? |
| 18 Jun 2021 |
Biotech Daily |
Dr Boreham’s Crucible: Actinogen Medical |
| 16 Jun 2021 |
The Motley Fool |
Why is the Actinogen (ASX:ACW) share price up 414% in 3 months? |
| 10 Jun 2021 |
Stockhead |
Check Up: As Alzheimer’s grabs the spotlight, these ASX biotech stocks also impressed |
| 10 Jun 2021 |
Share Cafe |
Alzheimer’s Decision Sends Positive Message to Aussie Biotechs |
| 08 Jun 2021 |
Stockhead |
FDA’s landmark approval of Biogen’s Alzheimer’s drug sends Cogstate up 60 per cent |
| 04 Jun 2021 |
Stockhead |
Actinogen to progress Alzheimer’s study |
| 02 Jun 2021 |
The Market Herald |
Actinogen Medical (ASX:ACW) granted ethics committee approval for Alzheimers study |
| 02 Jun 2021 |
Biotech Daily |
Actinogen: Part-A Xanamia Xanamem Cognition Trial Approved |
| 22 Apr 2021 |
Biotech Daily |
Actinogen Plans Three Phase II Cognition Trials For 2022 |
| 15 Apr 2021 |
The Motley Fool |
Actinogen (ASX:ACW) share price surges 23% today, 165% this year |
| 15 Mar 2021 |
Biotech Daily |
Actinogen Appoints Dr Steven Gourlay CEO On $400k |
| 15 Mar 2021 |
The Market Herald |
Actinogen Medical (ASX:ACW) appoints new CEO |
| 11 Feb 2021 |
Biotech Daily |
Actinogen Shortfall Raises $3.55m – Total $10.9m |
| 05 Feb 2021 |
The Market Herald |
Actinogen (ASX:ACW) nabs FDA designation for Fragile X treatment |
| 20 Nov 2020 |
Biotech Daily |
Dr Boreham’s Crucible: Actinogen Medical |
| 13 Nov 2020 |
Biotech Daily |
Actinogen Rights Raise $1.4m Of Hoped-For $4.9m – Total $7.4m |
| 09 Nov 2020 |
The Market Herald |
Actinogen Medical (ASX:ACW) files new patent applications |
| 09 Nov 2020 |
The Motley Fool |
Actinogen Medical (ASX:ACW) share price jumps on patent news |
